Cord blood transplantation from sibling donors in Japan. Report of the national survey.
A joint national survey on cord blood transplantation (CBT) was conducted in Japan and 18 sibling CBTs were reported. Diseases of the patients were leukemia (ten), neuroblastoma (one), bone marrow failure (four) and inborn errors of metabolism (three). A volume of 50-141 ml of cord blood containing 27-197 x 10(7) nucleated cells was collected from sibling infants soon after delivery. HLA antigens were identical in 14 and one to three antigens mismatched in four. Engraftment of donor cord blood was achieved in 17 cases. Autologous hematopoiesis was recovered in one case. Days of engraftment were 13-29 days (median 19 days) for neutrophils (500/microliter), 18-67 days (median 30 days) for reticulocytes (2%) and 21-96 days (median 46 days) for platelets (50 x 10(3)/microliter). Acute GVHD was grade 0 in seven cases, grade I in five cases and grade II in one case in HLA-identical pairs, but became grade II in two cases and grade III in two cases in HLA-mismatched pairs. Chronic GVHD of limited type developed in two out of 17 evaluable cases, however both responded to immunosuppressive therapy. Altogether, 14 out of 18 patients are currently surviving 4-27 months following transplantation. Probabilities of overall survival and disease free survival were estimated to be 77.0 and 71.8% using Kaplan-Meier tests. These findings suggest the feasibility of cord blood transplantation from sibling donors and the possibility of unrelated cord blood transplantation. A cord blood banking system is necessary for the universal use of cord blood stem cells from unrelated donors.
Kato
S
S
Department of Pediatrics, Tokai University School of Medicine, Kanagawa, Japan.
Nishihira
H
H
Sako
M
M
Kato
K
K
Azuma
E
E
Kawano
Y
Y
Kawa
K
K
Kinoshita
A
A
Sugita
K
K
Sugi
Y
Y
Okimoto
Y
Y
Inamitsu
T
T
D000741:Anemia, Aplastic / Q000401:mortality / Q000628:therapy; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology; D006306:Health Surveys; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data*; D006648:Histocompatibility; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan / Q000453:epidemiology; D007938:Leukemia / Q000401:mortality / Q000628:therapy; D015993:Life Tables; D008297:Male; D008661:Metabolism, Inborn Errors / Q000628:therapy; D009447:Neuroblastoma / Q000628:therapy; D009679:Nuclear Family; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000706:statistics & numerical data; D016896:Treatment Outcome